| Literature DB >> 25512687 |
Shilpi Singh1, Urmi Bajpai2, Andrew Michael Lynn3.
Abstract
UNLABELLED: The Mur E enzyme of Mur pathway of Mycobacterium tuberculosis is an attractive drug target as it is unique to bacteria and is absent in mammalian cells. The virtual screening of large libraries of drug like molecules against a protein target is a common strategy used to identify novel inhibitors. However, the method has a large number of pitfalls, with large variations in accuracy caused in part by inaccurate protocols, use of improper standards and libraries, and system dependencies such as the potential for nonspecific docking from large active-site cavities. The screening of drug-like small molecules from diversity sets can, however, be used to short-list potential fragments as building blocks to generate leads with improved specificity. We describe a protocol to implement this strategy, which involves an analysis of the active site and known inhibitors to identify orthospecific determinants, virtual screening of a drug-like diversity library to identify potential drug primitives, and inspection of the potential docked fragments for both binding potential and toxicity. The protocol is implemented on the M.tb Mur E protein which has a large active site with poor enrichment of known positives and a set of drug-like molecules that meets this criteria is presented for further analysis. ABBREVIATIONS: MTB - Mycobacterium tuberculosis, NCI - National Cancer Institute, PDB - Protein Databank.Entities:
Keywords: Molecular Docking; Mur E inhibitors; Mycobacterium tuberculosis; PDB ID: 2XJA; Virtual Screening
Year: 2014 PMID: 25512687 PMCID: PMC4261115 DOI: 10.6026/97320630010697
Source DB: PubMed Journal: Bioinformation ISSN: 0973-2063
Figure 1A) The M. tb Mur E enzyme (2xja) with the active site grid used for docking visible as a mesh. Critical residues of importance for natural ligand are shown as spheres. The associated ADP and magnesium in orange and green color respectively; B) Critical residues responsible for binding can be defined from the X-RAY and docked ligand: Ser222, Asp247, His248, Thr195, Thr196, Arg 230, Glu198, Leu67, Ser84, Ala69,Gln70, Thr8 and Thr85 residues interact with the natural substrate Uridine-5'- Diphosphate-N-Acetylmuramoyl-L-Alanine-D-Glutamate. LIGPLOT superimposition shows overlap at eighteen places which supports the docking algorithm being followed. The post docking ligand showed proximity with 10 out of the 13 earlier identified specificity determining residues that interact with the natural substrate. The superimposed pre and post docked conformations of the of natural substrate shows that the linear tail corresponding to the di-peptide (C21 to C28) is correctly docked in the groove of the active site (average RMSD of C21-C28 = 0.9671), while the UDP moiety has a higher RMSD of 3.753. The orange and green labels correspond to section I & II, respectively.
Figure 2A) Rank plot of known positives after docking. SID 103691194 is separated adequately from the decoys; B) Prediction of potential inhibitors from libraries: A histogram plot of the docking energies of the NCI diversity set. The energies of known positives are shown as bars on the X-axis.
Figure 3Comparison of positive controls and predicted inhibitors: interacting residues after docking
Figure 4Ligplot results for post-docking poses of selected ligands A) Uridine-5'-Diphosphate-N-Acetylmuramoyl-L-Alanine-DGlutamate- (Natural Ligand.); B) SID 103691194 (Known inhibitor for E.Coli); C) SID 26732564 and; D) SID 26664473.